1. Executive Summary (Confidence: high)

Abionic represents a significant shift in the diagnostic landscape, moving from centralized, time-consuming laboratory processes to immediate, actionable insights at the point of care.^[1] The organization’s value proposition is centered on its abioSCOPE platform, which leverages nanofluidics to reduce the time-to-result for critical conditions like sepsis from several hours to approximately five to seven minutes.^[2] This acceleration is vital in acute care settings where every hour of delay in treatment correlates with a significant increase in patient mortality. Throughout 2024 and 2025, Abionic achieved critical milestones, most notably receiving FDA 510(k) clearance for its Pancreatic Stone Protein (PSP) sepsis test, which facilitates the company's entry into the high-value United States healthcare market.^[4] By partnering with industrial leaders like Benchmark for engineering and manufacturing, Abionic has successfully transitioned from a research-heavy startup to a commercially viable scale-up with a robust, cost-optimized hardware platform.^[2]